Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) reports a corporate governance event dated September 22, 2025. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of John R. Palumbo as a Class B director, effective September 22, 2025. Mr. Palumbo was designated by holders of the Company's 12% Convertible Secured Promissory Notes Due 2029, exercising a collective right granted under the Convertible Notes agreements.
Outlook, Risks, and Management Commentary
- Compensation: The Company entered into a standard indemnification agreement with Mr. Palumbo. He will receive cash fees and equity awards consistent with the existing policy for non-employee directors.
- Related Party Transactions: The filing states Mr. Palumbo has not engaged in any transactions requiring reporting under Item 404(a) of Regulation S-K.
- Disclosure: A press release regarding this appointment was issued on September 25, 2025, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms of the 12% Convertible Secured Promissory Notes Due 2029 to understand the debt obligations and conversion rights associated with the director designation.
- Review the Company's existing compensation policy for non-employee directors to assess the potential equity dilution from awards granted to Mr. Palumbo.
- Confirm the composition of the Board of Directors following this appointment to evaluate governance structure changes.